WO2015007520A1 - Targeting of cytokine antagonists - Google Patents
Targeting of cytokine antagonists Download PDFInfo
- Publication number
- WO2015007520A1 WO2015007520A1 PCT/EP2014/063976 EP2014063976W WO2015007520A1 WO 2015007520 A1 WO2015007520 A1 WO 2015007520A1 EP 2014063976 W EP2014063976 W EP 2014063976W WO 2015007520 A1 WO2015007520 A1 WO 2015007520A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- fusion protein
- cytokine
- antagonist
- antibody
- Prior art date
Links
- 230000008685 targeting Effects 0.000 title claims abstract description 24
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 22
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 22
- 239000005557 antagonist Substances 0.000 title claims description 26
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 36
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 36
- 239000000430 cytokine receptor antagonist Substances 0.000 claims abstract description 22
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 201000011510 cancer Diseases 0.000 claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims description 49
- 208000023275 Autoimmune disease Diseases 0.000 claims description 13
- 210000002865 immune cell Anatomy 0.000 claims description 13
- 239000003550 marker Substances 0.000 claims description 8
- 108010050904 Interferons Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 abstract description 10
- 108020003175 receptors Proteins 0.000 abstract description 10
- 230000011664 signaling Effects 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 27
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 27
- 230000000694 effects Effects 0.000 description 22
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 9
- 102000000589 Interleukin-1 Human genes 0.000 description 9
- 108010002352 Interleukin-1 Proteins 0.000 description 9
- 102100033461 Interleukin-17A Human genes 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 description 8
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 description 8
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 7
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 102100031775 Leptin receptor Human genes 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000010468 interferon response Effects 0.000 description 4
- 108010019813 leptin receptors Proteins 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 3
- 208000011594 Autoinflammatory disease Diseases 0.000 description 3
- 101001019598 Homo sapiens Interleukin-17 receptor A Proteins 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- -1 I L-1 Proteins 0.000 description 3
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 3
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 3
- 102100035018 Interleukin-17 receptor A Human genes 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 229960004238 anakinra Drugs 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 244000309459 oncolytic virus Species 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 2
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 2
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 2
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- 101001129925 Mus musculus Leptin receptor Proteins 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 2
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 2
- 102100035721 Syndecan-1 Human genes 0.000 description 2
- 210000000068 Th17 cell Anatomy 0.000 description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- JFINOWIINSTUNY-UHFFFAOYSA-N pyrrolidin-3-ylmethanesulfonamide Chemical compound NS(=O)(=O)CC1CCNC1 JFINOWIINSTUNY-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 1
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 description 1
- 101001019602 Homo sapiens Interleukin-17 receptor C Proteins 0.000 description 1
- 229940126060 IL-17A antagonist Drugs 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 description 1
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 102100035012 Interleukin-17 receptor C Human genes 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010029176 Sialic Acid Binding Ig-like Lectin 1 Proteins 0.000 description 1
- 102100032855 Sialoadhesin Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960003735 brodalumab Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960005435 ixekizumab Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229950010316 rontalizumab Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229950010077 sifalimumab Drugs 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- CBPNZQVSJQDFBE-HGVVHKDOSA-N temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Definitions
- the present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or antibody like molecule.
- the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling.
- the invention relates further to a fusion protein according to the invention for use in treatment of cancer or for use in treatment of autoimmune diseases.
- Cytokines are critical mediators of defence mechanisms against microbial invasion and tumorigenesis. However, their production and activities must be tightly regulated to prevent an excessive activity that can culminate in the uncontrolled inflammation and tissue injury, as characteristically observed with many autoimmune diseases.
- Rheumatoid arthritis is the classic example of an autoimmune disease where TNFa, I L-1 , and IL-6 play a prominent role in the recruitment of lymphocytes and other types of leukocytes that mediate a progressive joint destruction. TNF inhibitors have been shown to decrease symptoms, slow disease progression, and improve the quality of life for many patients with rheumatoid arthritis (Moreland, 2009).
- a mAb neutralizing IL-12 and IL-23 provides a potential therapy for psoriasis (Elliott et al., 2009) and a recombinant human IL-1 receptor antagonist, (anakinra, KineretTM), first approved by the FDA in 2001 for the treatment of rheumatoid arthritis, is a promising agent for the treatment of many IL-1 - mediated autoinflammatory diseases (Goldbach-Mansky, 2009).
- IL17A is the best characterized member of the IL17 family of cytokines. This pleiotropic cytokine interacts with a receptor composed of IL17RA and IL17RC subunits.
- the IL17RA chain is ubiquitously expressed, including haematopoietic, immune, epithelial, endothelial cell types, as well as fibroblasts.
- IL17A is typically produced by Th17 cells upon activation by a subset of cytokines including IL-1 , IL-6, IL-21 and TGFp, and propagates early inflammatory signals that serve to bridge innate and adaptive immune responses.
- IL17 is a potent activator of neutrophils and plays an important role in the immune defence against various extracellular pathogens.
- IL17A promotes autoimmune pathologies (Gaffen, 2009; Shen & Gaffen, 2008).
- Brodalumab, Secukinumab and Ixekizumab target the IL17A/IL17R axis for treatment of auto-immune diseases such as psoriasis and Crohn's disease. All may inflict adverse side effects including enhanced risk of infections (Hueber et al. 2012; Spuls & Hooft, 2012).
- IL17A antagonists may therefore offer a significant advantage over completely antagonising IL17 function.
- ILI a and ⁇ _ ⁇ are the founding members of the IL1 cytokine family. Both are pleiotropic and function through a ubiquitously expressed receptor complex composed of IL-1 receptor type-l (IL-1 RI) and IL-1 receptor accessory protein (IL-1 RAcP). Overactivation of this IL-1 axis is associated with many human pathologies including rheumatoid arthritis (RA), chronic obstructive pulmonary disease (COPD), asthma, inflammatory bowel diseases, multiple sclerosis, atherosclerosis and Alzheimer's disease.
- RA rheumatoid arthritis
- COPD chronic obstructive pulmonary disease
- asthma inflammatory bowel diseases
- multiple sclerosis multiple sclerosis
- atherosclerosis atherosclerosis
- Alzheimer's disease Alzheimer's disease.
- IL-1 immune cells of different lineages are activated by IL-1 , including innate immune cells such as dendritic cells, macrophages and neutrophils, and also cells involved in the adaptive immune response including naive, Th17 and CD8+ T cells, and B cells (reviewed in Sims and Smith, 2010).
- Recombinant human IL- 1 RA IL1 receptor antagonist, aka anakinra
- autoinflammatory diseases Disperello, 201 1 .
- One of the major side effects of prolonged treatment with anakinra is however the increased occurrence of infections.
- IL-1 activity on only a subset of (immune) cells therefore may offer a safer alternative. It can be envisaged that targeted inhibition of IL-1 action on selected innate immune cells, leaving its activity on the T cell compartment intact, may still show efficacy for the treatment of inflammatory diseases, without affecting the host defence against pathogens.
- TSLP thymic stromal lymphopoietin
- IL-7Ra IL-7 receptor
- TSLPRa TSLPRa
- TSLP promotes Th2-type inflammation by acting on several distinct cell types, including dendritic cells, CD4 and CD8 T cells, B cells, NKT cells, mast cells, eosinophils and basophils.
- TSLP can have a protective role in inflammatory diseases driven by exacerbated Th1 and Th17 responses, such as Inflammatory Bowel Disease (reviewed in He and Geha, 2010 and Roan et al., 2012).
- the main problem with the therapeutic approaches aiming to neutralize cytokine actions is that the cytokine antagonists are not targeted towards cells or tissues that are specifically involved in the onset of the autoimmune or autoinflammatory diseases.
- a long term systemic neutralization of type I IFN activity by a monoclonal antibody or an IFN receptor antagonist carry an important risk in term of viral infection susceptibility and tumor development since type I IFN is a family of proteins essential in the control of viral infections and for establishing immune responses, particularly those controlling cancer cell growth (Gajewski et al., 2012).
- a systemic neutralization of IL-1 activity will impact the expansion, effector function, tissue localization, and memory response of antigen-cytotoxic T cells during immune responses (Ben-Sasson et al., 2013).
- the invention is exemplified by targeting the action of a type I IFN antagonist to specific cell types expressing a given cell surface marker.
- Such a method is applied to the design and construction of a targeted IFN antagonist that inhibits the action of endogenous IFN specifically on the cell subset culpably involved in the onset of autoimmune diseases, leaving the other cells and organs fully responsive.
- Oncolytic viruses are advancing through clinical trials (Russell et al., 2012). Oncolytic viruses are often designed for having attenuated replication capacity in normal tissues by engineering their sensitivity to the normal cellular interferon-mediated antiviral responses.
- An example is an oncolytic vesicular stomatitis virus coding for interferon ⁇ (Naik et al., 2012). The therapeutic effect of such viruses is expected to be a consequence of the defect of the IFN response exhibited by many tumor cells.
- the genetic heterogeneity of tumors that impact the IFN response is highly variable and impairs the efficacy of virus-mediated tumor lysis (Naik and Russell, 2009).
- a first aspect of the invention is a fusion protein comprising a cytokine antagonist and a targeting moiety consisting of an antibody or an antibody like molecule.
- a cytokine antagonist as used here can be any cytokine antagonist known to the person skilled in the art, including but not limited to a soluble receptor, a cytokine binding antibody or a mutant cytokine.
- said cytokine antagonist is a mutant cytokine, even more preferably a mutant which binds to the receptor, but is not or only weakly inducing the cytokine signalling.
- the affinity of the mutant for the receptor is comparable to that of the wild type cytokine, even more preferable it has a higher affinity; preferably the signalling induced by the mutant is less than 20% of that of the wild type, even more preferably less than 10% of that of the wild type, even more preferably less than 5%, even more preferably less than 1 %. Most preferably, the binding of the mutant cytokine does not result in detectable signalling. Such mutant can act as a competitive inhibitor of cytokine signalling.
- An antibody or antibody like molecule as used here is a protein specifically designed to bind another molecule, preferably a proteineous molecule, and comprising the specific binding domains.
- said antibody or antibody like molecule can be a heavy chain antibody (hcAb), single domain antibody (sdAb), minibody (Tramontano et al., 1994), the variable domain of camelid heavy chain antibody (VHH), the variable domain of the new antigen receptor (VNAR), affibody (Nygren et al., 2008), alphabody (WO2010066740), designed ankyrin-repeat domain (DARPins) (Stumpp et al., 2008), anticalin (Skerra et al., 2008), knottin (Kolmar et al., 2008) and engineered CH2 domain (nanoantibodies; Dimitrov, 2009).
- hcAb heavy chain antibody
- sdAb single domain antibody
- minibody Tramontano et al., 1994
- VHH camelid heavy chain antibody
- VNAR variable domain of the new antigen receptor
- affibody Nygren et al., 2008
- alphabody WO201006
- said antibody or antibody like molecule consists of a single polypeptide chain, even more preferably, said antibody is not post-translationally modified.
- Prost-translational modification indicates the modifications carried out by living cell during or after the protein synthesis, but excludes modifications, preferably chemical modifications, carried out on the isolated protein such as, but not limited to pegylation Even more preferably said antibody or antibody-like molecule comprises the complementary determining regions, derived from an antibody.
- said targeting antibody or antibody-like molecule is a nanobody.
- said cytokine antagonist and said targeting moiety are connected by a linker, preferably a GGS linker.
- a linker preferably a GGS linker.
- said GGS linker contains at least 5 GGS repeats, more preferably at least 10 GGS repeats, even more preferably at least 15 GGS repeats, most preferably at least 20 GGS repeats.
- the cytokine antagonist according to the invention is an interferon antagonist; even more preferably, it is an IFNa2-R120E mutant.
- the cytokine antagonist according to the invention is an antagonist of a cytokine of the IL17 family, preferably an IL17A antagonist.
- the cytokine antagonist according to the invention is an antagonist of the IL1 cytokine family, preferably an ILI a or ILp antagonist.
- the cytokine antagonist according to the invention is a TSLP antagonist.
- the antibody or antibody-like molecule is directed against a cancer cell marker.
- Cancer cell markers are known to the person skilled in the art, and include, but are not limited to CD19, CD20, CD22, CD30, CD33, CD37, CD56, CD70, CD74, CD138, AGS16, HER2, MUC1 , GPNMB and PMSA.
- said cancer marker is CD20 or HER2.
- the antibody or antibody-like molecule is directed against a marker on an immune cell, preferably an inflammatory cytokine producing immune cell.
- An immune cell as used here, is a cell that belongs to the immune system, including but not limited to monocytes, dendritic cells and T-cells.
- said immune cell is a proinflammatory cytokine producing cell.
- Markers of inflammatory cytokine producing cells include but are not limited to CD4, CD1 1 b, CD26, sialoadhesin and flt3 receptor.
- Another aspect of the invention is a fusion protein according to the invention for use in treatment of cancer. Still another aspect of the invention is a fusion protein according to the invention for use in treatment of autoimmune diseases.
- Another aspect of the invention is a method to treat cancer, comprising (i) determination the type of cancer and the suitable targeting marker(s) for the cancer cells in a patient suffering from cancer (ii) providing to said patient in need of the treatment a fusion protein comprising a cytokine antagonist and a targeting moiety consisting of an antibody or an antibody-like molecule according to the invention, possibly with a suitable excipient. It is obvious for the person skilled in the art that the targeting moiety of step (ii) will be directed to the targeting marker identified in step (i).
- Possible cancer cell markers are known to the person skilled in the art, and include, but are not limited to CD19, CD20, CD22, CD30, CD33, CD37, CD56, CD70, CD74, CD138, AGS16, HER2, MUC1 , GPNMB and PMSA.
- Still another aspect of the invention is a method to treat an autoimmune disease, comprising (i) determination in a patient suffering from an autoimmune disease the suitable targeting marker(s) for the immune cells cells cells (ii) providing to said patient in need of the treatment a fusion protein comprising a cytokine antagonist and a targeting moiety consisting of an antibody or an antibody-like molecule according to the invention, possibly with a suitable excipient.
- Immune cells include but are not limited to dendritic cells, CD4 and CD8 T cells, B cells, NKT cells, mast cells, eosinophils and basophils.
- Figure 1 Representation of the structural elements of the nanobody-hlFNa2-R120E fusion protein.
- Figure 2 Quantification of the luciferase activity induced by 10 pM hl FNa2 in the presence or absence (untreated) of the 4-1 1 -hl FNa2-R120E fusion protein on HL1 16 (A) and HL1 16- ml_R10 (B) cells.
- Figure 3 Quantification of the luciferase activity induced by 1 pM IFN3 in the presence or absence (untreated) of the 4-1 1 -hl FNa2-R120E fusion protein on HL1 16 (A) and HL1 16- ml_R10 (B) cells.
- Figure 4 FACS analysis of pY701 -STAT1 in CD19 positive and negative human PBMCs left untreated (left panel), treated with 50 pM of hl FNa2 (center) or with 50 pM of hl FNa2 in the presence of the CD20-targeted I FN antagonist.
- Nanobody-I FN antagonist fusion construction Nanobody-I FN antagonist fusion construction.
- Hek 293T cells were transfected with the protein fusion constructs using the standard lipofectamin method (Invitrogen). 48 hours after the transfection culture mediums were harvested and stored at -20°C. Cell lines
- Hek 293T cells were grown in DMEM supplemented with 10% FCS.
- the HL1 16 clone (Uze et al., 1994) is derived from the human HT1080 cell line. It contains the firefly luciferase gene controlled by the IFN-inducible 6-16 promoter.
- the derived HL1 16-mLR10 clone which expresses the murine leptin receptor was described (PCT/EP2013/050787).
- Antagonistic IFN activities were measured by quantifying the inhibition of the luciferase activity induced in HL1 16 cells and on the HL1 16-ml_R10 expressing the rmLR by IFNa2 or IFN3.
- the IC50 values were calculated using nonlinear data regression with Prism software (GraphPad).
- Luciferase activities were determined on a Berthold Centra LB960 luminometer using a luciferase substrate buffer (20 mM Tricine, 1.07 mM (MgC03)4Mg(OH)2 « 5H20, 2.67 mM MgS04 « 7H20, 0.1 mM EDTA, 33.3 mM dithiothreitol, 270 ⁇ coenzyme A, 470 ⁇ luciferin, 530 ⁇ ATP, final pH 7.8) after 6hr IFN stimulation.
- a luciferase substrate buffer (20 mM Tricine, 1.07 mM (MgC03)4Mg(OH)2 « 5H20, 2.67 mM MgS04 « 7H20, 0.1 mM EDTA, 33.3 mM dithiothreitol, 270 ⁇ coenzyme A, 470 ⁇ luciferin, 530 ⁇ ATP, final pH 7.8) after 6hr IFN stimulation.
- Example 1 The nanobody-IFNa2-R120E fusion protein.
- the nanobody 4-1 1 directed against the murine leptin receptor was fused to the IFNa2 mutant R120E as described in the materials and methods
- Figure 1 shows a schematic representation of the nanobody-IFN antagonist fusion protein constructed with the nanobody 4-1 1 against the murine leptin receptor and the human IFNa2- R120E (numbering as in Piehler et al., 2000).
- Example 2 Targeted inhibition of IFNa activity on mLR-expressing cells
- Example 3 Targeted inhibition of IFN activity on mLR-expressing cells
- the IFN3 shows the highest affinity for the IFNa/ ⁇ receptor. We thus tested whether the 4-1 1 -IFNa2-R120E fusion protein exerts also an antagonistic activity against IFN3 action.
- Parental HL1 16 cells and the derived HL1 16-mLR10 cells which express the mouse leptin receptor were treated for 6 hours with 1 pM IFN3 in the presence of several dilutions of culture medium conditioned by Hek 293T cells expressing the 4-1 1 -IFNa2-R120E fusion protein.
- the 1 pM IFN3 dose was chosen because it corresponds to the IFN3 EC50 on both cell lines. Cells were then lysed and the IFN-induced luciferase activity was quantified.
- the 4-1 1 -IFNa2-R120E fusion protein was unable to inhibit IFNa2 action on untargeted HL1 16 cells (Figure 3A).
- its dose-dependent inhibition effect is clear on HL1 16-mLR10 cells which express the target of the 4-1 1 nanobody ( Figure 3B).
- the type I IFN antagonist IFNa2-R120E was fused to the anti-human CD20 nanobody 2HCD25 through a linker sequence made with 20 repeats of GGS motif.
- the fusion protein was produced in E. coli and purified by Immobilized Metal Affinity chromatography (IMAC).
- IMAC Immobilized Metal Affinity chromatography
- PBMCs peripheral blood mononuclear cells
- FIG 4 shows that the IFN antagonist linked to the nanobody specific for CD20 inhibits the IFN action specifically in the major part of the B cell population, leaving intact the IFN response in the CD19 negative cell population.
- Example 5 The CD20-targeted type I IFN antagonist inhibits the antiproliferative activity of type I IFN.
- the fusion protein of the 2HCD25 nanobody and IFNa2-R120E inhibits IFN-induced STAT1 phosphorylation specifically in B-cells.
- Daudi cells are a human lymphoblastoid B-cell line expressing CD20. Daudi cells were seeded at 2.0x105 cells/ml and were left untreated or cultured for 72 h in the presence of 2 pM IFNa2 alone or in combination with various CD20-targeted IFN antagonists. They were then counted to estimate the efficacy of the inhibition of proliferation induced by IFNa2.
- Figure 5 shows that the CD20-targeted IFN antagonist fully inhibits the antiproliferative activity of IFNa2. It also shows that decreasing the IFN-IFNAR2 affinity decreases the antagonistic activity, proving that the inhibitory effect is indeed due to the binding of the targeted antagonist.
- IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J Exp Med 210, 491 -502.
- Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J. Exp Med 208, 469-478).
- Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1 , Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 1 15, 5312-5321 .
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11201600165WA SG11201600165WA (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
EP14734166.3A EP3022230B1 (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
CN201480040656.4A CN105658669A (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
AU2014292355A AU2014292355B2 (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
JP2016526507A JP6475712B2 (en) | 2013-07-19 | 2014-07-01 | Targeting cytokine antagonists |
KR1020167002677A KR102305608B1 (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
CA2918119A CA2918119C (en) | 2013-07-19 | 2014-07-01 | Targeting of ifn.alpha.2 antagonists to treat autoimmune diseases |
US14/905,348 US9732135B2 (en) | 2013-07-19 | 2014-07-01 | Targeting of human interferon antagonists |
MX2016000721A MX2016000721A (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists. |
IL24345916A IL243459B (en) | 2013-07-19 | 2016-01-04 | Targeting of cytokine antagonists |
US15/642,989 US10072059B2 (en) | 2013-07-19 | 2017-07-06 | Targeting of human interferon antagonists |
US16/008,686 US10947288B2 (en) | 2013-07-19 | 2018-06-14 | Targeting of human interferon antagonists |
US16/008,695 US20180334489A1 (en) | 2013-07-19 | 2018-06-14 | Targeting of cytokine antagonists |
US17/171,433 US20210238247A1 (en) | 2013-07-19 | 2021-02-09 | Targeting of human interferon antagonists |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13306045.9 | 2013-07-19 | ||
EP13306045 | 2013-07-19 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/905,348 A-371-Of-International US9732135B2 (en) | 2013-07-19 | 2014-07-01 | Targeting of human interferon antagonists |
US15/642,989 Continuation US10072059B2 (en) | 2013-07-19 | 2017-07-06 | Targeting of human interferon antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015007520A1 true WO2015007520A1 (en) | 2015-01-22 |
Family
ID=48874233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/063976 WO2015007520A1 (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
Country Status (11)
Country | Link |
---|---|
US (5) | US9732135B2 (en) |
EP (1) | EP3022230B1 (en) |
JP (1) | JP6475712B2 (en) |
KR (1) | KR102305608B1 (en) |
CN (1) | CN105658669A (en) |
AU (1) | AU2014292355B2 (en) |
CA (1) | CA2918119C (en) |
IL (1) | IL243459B (en) |
MX (1) | MX2016000721A (en) |
SG (2) | SG11201600165WA (en) |
WO (1) | WO2015007520A1 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
WO2017134305A1 (en) | 2016-02-05 | 2017-08-10 | Orionis Biosciences Nv | Bispecific signaling agents and uses thereof |
WO2017153345A1 (en) * | 2016-03-07 | 2017-09-14 | Vib Vzw | Cd20 binding agents and uses thereof |
WO2017153402A1 (en) | 2016-03-07 | 2017-09-14 | Vib Vzw | Cd20 binding single domain antibodies |
WO2017194782A2 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Therapeutic targeting of non-cellular structures |
WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
WO2018077893A1 (en) | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
WO2018141964A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences Nv | Targeted chimeric proteins and uses thereof |
WO2018144999A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
WO2018146074A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
WO2021009332A1 (en) | 2019-07-18 | 2021-01-21 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
US11440943B2 (en) | 2019-03-28 | 2022-09-13 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
US11498966B2 (en) | 2017-08-09 | 2022-11-15 | Orionis Biosciences Inc. | PD-1 and PD-L1 binding agents |
WO2022258662A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
US11566072B2 (en) | 2017-08-09 | 2023-01-31 | Orionis Biosciences, Inc. | CD8 binding agents |
US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
US11896643B2 (en) | 2018-02-05 | 2024-02-13 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
WO2024040249A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
WO2024040247A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2804877B1 (en) * | 2012-01-20 | 2018-08-22 | VIB vzw | Targeted mutant alpha-helical bundle cytokines |
KR102305608B1 (en) * | 2013-07-19 | 2021-09-28 | 브이아이비 브이지더블유 | Targeting of cytokine antagonists |
CN111499718B (en) * | 2019-01-30 | 2022-06-14 | 复旦大学 | Human alpha interferon receptor binding related site mutant and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010066740A1 (en) | 2008-12-08 | 2010-06-17 | Complix Nv | Single-chain antiparallel coiled coil proteins |
US20130183298A1 (en) * | 1991-03-18 | 2013-07-18 | New York University | Methods of Treating Hepatitis With Anti-TNF alpha Antibodies |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0489116B1 (en) | 1989-08-22 | 1994-04-06 | Immunex Corporation | Fusion proteins comprising gm-csf and il-3 |
US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
ES2243995T3 (en) * | 1996-04-26 | 2005-12-01 | Beth Israel Deaconess Medical Center, Inc. | INTERLEUCINE ANTAGONISTS-15. |
US6617135B1 (en) * | 1999-08-09 | 2003-09-09 | Emd Lexigen Research Center Corp. | Multiple cytokine protein complexes |
US20020193569A1 (en) * | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
CA2585549A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Novel type leptin receptor antagonist |
WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
EP2476428B1 (en) * | 2005-06-29 | 2013-08-21 | Yeda Research and Development Co. Ltd. | Recombinant interferon alpha 2 (IFN alpha 2) mutants |
CA2693326A1 (en) | 2006-08-02 | 2008-02-07 | Mcgill University | Gm-csf and il-15 fusokines and methods for modulation of the immune response |
WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
CN104109200B (en) * | 2007-05-11 | 2018-03-20 | 阿尔托生物科学有限公司 | Fusion molecule and the variants of IL 15 |
WO2009003145A1 (en) | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
EP2853267B1 (en) | 2007-09-21 | 2016-12-07 | The Regents of the University of California | Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
US20110224407A1 (en) * | 2008-09-09 | 2011-09-15 | University Of Medicine And Dentistry Of New Jersey | Type I Interferon Antagonists |
WO2010036918A2 (en) | 2008-09-26 | 2010-04-01 | University Of Massachusetts | Intracellular dna receptor |
ES2534085T3 (en) | 2009-08-17 | 2015-04-17 | Roche Glycart Ag | Targeted Immunoconjugates |
EP2475397A1 (en) | 2009-09-10 | 2012-07-18 | Cytos Biotechnology AG | Use of interleukin-1 beta mutein conjugates in the treatment of diabetes |
US9534056B2 (en) | 2011-06-06 | 2017-01-03 | Immungene Inc | Engineered TAA antibody-TNFSF member ligand fusion molecules |
JP6184965B2 (en) * | 2011-10-28 | 2017-08-23 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Polypeptide constructs and uses thereof |
EP2804877B1 (en) * | 2012-01-20 | 2018-08-22 | VIB vzw | Targeted mutant alpha-helical bundle cytokines |
EP2822575B1 (en) | 2012-03-03 | 2020-05-06 | ImmunGene, Inc. | Engineered antibody-interferon mutant fusion molecules |
KR102305608B1 (en) * | 2013-07-19 | 2021-09-28 | 브이아이비 브이지더블유 | Targeting of cytokine antagonists |
-
2014
- 2014-07-01 KR KR1020167002677A patent/KR102305608B1/en active IP Right Grant
- 2014-07-01 MX MX2016000721A patent/MX2016000721A/en active IP Right Grant
- 2014-07-01 US US14/905,348 patent/US9732135B2/en active Active
- 2014-07-01 WO PCT/EP2014/063976 patent/WO2015007520A1/en active Application Filing
- 2014-07-01 JP JP2016526507A patent/JP6475712B2/en active Active
- 2014-07-01 EP EP14734166.3A patent/EP3022230B1/en active Active
- 2014-07-01 AU AU2014292355A patent/AU2014292355B2/en active Active
- 2014-07-01 SG SG11201600165WA patent/SG11201600165WA/en unknown
- 2014-07-01 SG SG10202010429YA patent/SG10202010429YA/en unknown
- 2014-07-01 CA CA2918119A patent/CA2918119C/en active Active
- 2014-07-01 CN CN201480040656.4A patent/CN105658669A/en active Pending
-
2016
- 2016-01-04 IL IL24345916A patent/IL243459B/en active IP Right Grant
-
2017
- 2017-07-06 US US15/642,989 patent/US10072059B2/en active Active
-
2018
- 2018-06-14 US US16/008,695 patent/US20180334489A1/en not_active Abandoned
- 2018-06-14 US US16/008,686 patent/US10947288B2/en active Active
-
2021
- 2021-02-09 US US17/171,433 patent/US20210238247A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130183298A1 (en) * | 1991-03-18 | 2013-07-18 | New York University | Methods of Treating Hepatitis With Anti-TNF alpha Antibodies |
WO2010066740A1 (en) | 2008-12-08 | 2010-06-17 | Complix Nv | Single-chain antiparallel coiled coil proteins |
Non-Patent Citations (36)
Title |
---|
BEN-SASSON, S.Z.; HOGG, A.; HU-LI, J.; WINGFIELD, P.; CHEN, X.; CRANK, M.; CAUCHETEUX, S.; RATNER-HUREVICH, M.; BERZOFSKY, J.A.; N: "IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells", J EXP MED, vol. 210, 2013, pages 491 - 502 |
DE MONTE, L.; RENI, M.; TASSI, E.; CLAVENNA, D.; PAPA, I.; RECALDE, H.; BRAGA, M.; DI CARLO, V.; DOGLIONI, C.; PROTTI, M.P.: "Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer", J. EXP MED, vol. 208, 2011, pages 469 - 478 |
DIMITROV DIMITER S: "Engineered CH2 domains (nanoantibodies)", MABS, LANDES BIOSCIENCE, US, vol. 1, no. 1, 1 January 2009 (2009-01-01), pages 26 - 28, XP002596414, ISSN: 1942-0870 * |
DIMITROV, D.S.: "Engineered CH2 domains (nanoantibodies", MABS, vol. 1, 2009, pages 26 - 28, XP002596414 |
DINARELLO, C.A.: "Interleukin-1 in the pathogenesis and treatment of inflammatory diseases", BLOOD, vol. 117, 2011, pages 3720 - 3732, XP055146700, DOI: doi:10.1182/blood-2010-07-273417 |
ELLIOTT, M.; BENSON, J.; BLANK, M.; BRODMERKEL, C.; BAKER, D.; SHARPLES, K.R.; SZAPARY, P.: "Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases", ANN N Y ACAD SCI, vol. 1182, 2009, pages 97 - 110 |
ENSOR, H.M.; SCHWAB, C.; RUSSELL, L.J.; RICHARDS, S.M.; MORRISON, H.; MASIC, D.; JONES, L.; KINSEY, S.E.; VORA, A.J.; MITCHELL, C.: "Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial", BLOOD, vol. 117, 2011, pages 2129 - 2136 |
GAFFEN, S.L.: "Structure and signalling in the IL- 7 receptor family", NAT REV IMMUNOL, vol. 9, 2009, pages 556 - 567, XP055052444, DOI: doi:10.1038/nri2586 |
GAJEWSKI, T.F.; FUERTES, M.B.; WOO, S.R.: "Innate immune sensing of cancer: clues from an identified role for type I IFNs", CANCER IMMUNOL IMMUNOTHER, vol. 61, 2012, pages 1343 - 1347, XP035088690, DOI: doi:10.1007/s00262-012-1305-6 |
GOLDBACH-MANSKY, R.: "Blocking interleukin-1 in rheumatic diseases", ANN N Y ACAD SCI, vol. 1182, 2009, pages 111 - 123 |
HARVEY, R.C.; MULLIGHAN, C.G.; CHEN, I.M.; WHARTON, W.; MIKHAIL, F.M.; CARROLL, A.J.; KANG, H.; LIU, W.; DOBBIN, K.K.; SMITH, M.A.: "Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia", BLOOD, vol. 115, 2010, pages 5312 - 5321 |
HE, R.; GEHA, R.S.: "Thymic stromal lymphopoietin", ANN N Y ACAD SCI, vol. 1183, 2010, pages 13 - 24, XP008152987, DOI: doi:DOI: 10.1111/j.1749-6632.2009.05128.x |
HUEBER, W.; SANDS, B.E.; LEWITZKY, S.; VANDEMEULEBROECKE, M.; REINISCH, W.; HIGGINS, P.D.; WEHKAMP, J.; FEAGAN, B.G.; YAO, M.D.; K: "Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial", GUT, vol. 61, 2012, pages 1693 - 1700 |
KIEFER, K.; OROPALLO, M.A.; CANCRO, M.P.; MARSHAK-ROTHSTEIN, A.: "Role of type I interferons in the activation of autoreactive B cells", IMMUNOL CELL BIOL, vol. 90, 2012, pages 498 - 504 |
KOLMAR, H.: "Alternative binding proteins: biological activity and therapeutic potential of cysteine-knot miniproteins", FEBS J., vol. 275, 2008, pages 2684 - 2690, XP055417456, DOI: doi:10.1111/j.1742-4658.2008.06440.x |
MANJING PAN ET AL: "Mutation of the IFNAR-1 Receptor Binding Site of Human IFN-[alpha]2 Generates Type I IFN Competitive Antagonists +", BIOCHEMISTRY, vol. 47, no. 46, 18 November 2008 (2008-11-18), pages 12018 - 12027, XP055145910, ISSN: 0006-2960, DOI: 10.1021/bi801588g * |
MCBRIDE, J.M.; JIANG, J.; ABBAS, A.R.; MORIMOTO, A.; LI, J.; MACIUCA, R.; TOWNSEND, M.; WALLACE, D.J.; KENNEDY, W.P.; DRAPPA, J.: "Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase , placebo-controlled, double-blind, dose-escalation study", ARTHRITIS RHEUM, vol. 64, 2012, pages 3666 - 3676, XP002697719, DOI: doi:10.1002/ART.34632 |
MERRILL, J.T.; WALLACE, D.J.; PETRI, M.; KIROU, K.A.; YAO, Y.; WHITE, W.I.; ROBBIE, G.; LEVIN, R.; BERNEY, S.M.; CHINDALORE, V. ET: "Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase , multicentre, double-blind randomised study", ANN RHEUM DIS, vol. 70, 2011, pages 1905 - 1913, XP009169832, DOI: doi:10.1136/ard.2010.144485 |
MORELAND, L.W.: "Cytokines as targets for anti-inflammatory agents", ANN N Y ACAD SCI, vol. 1182, 2009, pages 88 - 96 |
NAIK, S.; NACE, R.; BARBER, G.N.; RUSSELL, S.J.: "Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta", CANCER GENE THER, vol. 19, 2012, pages 443 - 450 |
NAIK, S.; RUSSELL, S.J.: "Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways", EXPERT OPIN BIOL THER, vol. 9, 2009, pages 1163 - 1176 |
NYGREN, P-A.: "Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold", FEBS J., vol. 275, 2008, pages 2668 - 2676, XP002601623, DOI: doi:10.1111/J.1742-4658.2008.06438.X |
OLKHANUD, P.B.; ROCHMAN, Y.; BODOGAI, M.; MALCHINKHUU, E.; WEJKSZA, K.; XU, M.; GRESS, R.E.; HESDORFFER, C.; LEONARD, W.J.; BIRAGY: "Thymic stromal lymphopoietin is a key mediator of breast cancer progression", J. IMMUNOL., vol. 186, 2011, pages 5656 - 5662 |
PAN, M.; KALIE, E.; SCAGLIONE, B.J.; RAVECHE, E.S.; SCHREIBER, G.; LANGER, J.A.: "Mutation of the IFNAR-1 receptor binding site of human IFN-alpha2 generates type I IFN competitive antagonists", BIOCHEMISTRY, vol. 47, 2008, pages 12018 - 12027, XP055145910, DOI: doi:10.1021/bi801588g |
PANDEY, A.; OZAKI, K.; BAUMANN, H.; LEVIN, S.D.; PUEL, A.; FARR, A.G.; ZIEGLER, S.F.; LEONARD, W.J.; LODISH, H.F.: "Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin", NAT IMMUNOL., vol. 1, 2000, pages 59 - 64, XP008014551, DOI: doi:10.1038/76923 |
PIEHLER, J.; ROISMAN, L.C.; SCHREIBER, G.: "New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface", J. BIOL. CHEM, vol. 275, 2000, pages 40425 - 40433 |
ROAN, F.; BELL, B.D.; STOKLASEK, T.A.; KITAJIMA, M.; HAN, H.; ZIEGLER, S.F.: "The multiple facets of thymic stromal lymphopoietin (TSLP) during allergic inflammation and beyond", J LEUK BIOL, vol. 91, 2012, pages 877 - 886, XP008152989, DOI: doi:10.1189/jlb.1211622 |
RUSSELL, S.J.; PENG, K.W.; BELL, J.C.: "Oncolytic virotherapy", NAT BIOTECHNOL, vol. 30, 2012, pages 658 - 670, XP055164204, DOI: doi:10.1038/nbt.2287 |
SHEN, F.; GAFFEN, S.L.: "Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy", CYTOKINE, vol. 41, 2008, pages 92 - 104, XP022458527, DOI: doi:10.1016/j.cyto.2007.11.013 |
SIMS, J.E.; SMITH, D.E.: "The IL-1 family: regulators of immunity", NAT REV IMMUNOL, vol. 10, 2010, pages 89 - 102 |
SKERRA, A.: "Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities", FEBS J., vol. 275, 2008, pages 2677 - 2683, XP055099855, DOI: doi:10.1111/j.1742-4658.2008.06439.x |
SPULS, P.I.; HOOFT, L.: "Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal", BR J DERMATOL, vol. 167, 2012, pages 710 - 713 |
STUMP, M.T.; BINZ, H.K.; AMSTUTZ, P.: "DARPins: a new generation of protein therapeutics", DRUG ISCOV. TODAY, vol. 13, 2008, pages 695 - 701, XP023440383, DOI: doi:10.1016/j.drudis.2008.04.013 |
TRAMONTANO, A.; BIANCHI, E.; VENTURINI, S.; MARTIN, F.; PESSI, A; SOLLAZZO, M.: "The making of the minibody: an engineered beta-protein for the display of conformationally constrained peptides", J. MOL. RECOGNITION, vol. 7, 1994, pages 9 - 24 |
UZE, G.; DI MARCO, S.; MOUCHEL-VIELH, E.; MONNERON, D.; BANDU, M.T.; HORISBERGER, M.A.; DORQUES, A.; LUTFALLA, G.; MOGENSEN, K.E.: "Domains of interaction between alpha interferon and its receptor components", J MOL BIOL, vol. 243, 1994, pages 245 - 257, XP024008163, DOI: doi:10.1006/jmbi.1994.1651 |
YODA, A.; YODA, Y.; CHIARETTI, S.; BAR-NATAN, M.; MANI, K.; RODIG, S.J.; WEST, N.; XIAO, Y.; BROWN, J.R.; MITSIADES, C.: "Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia", PROC NATL ACAD SCI USA, vol. 107, 2010, pages 252 - 257, XP055169038, DOI: doi:10.1073/pnas.0911726107 |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11702477B2 (en) | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
EP3998281A1 (en) | 2016-02-05 | 2022-05-18 | Orionis Biosciences BV | Cd8 binding agents |
WO2017134305A1 (en) | 2016-02-05 | 2017-08-10 | Orionis Biosciences Nv | Bispecific signaling agents and uses thereof |
WO2017134302A2 (en) | 2016-02-05 | 2017-08-10 | Orionis Biosciences Nv | Targeted therapeutic agents and uses thereof |
US11236166B2 (en) | 2016-02-05 | 2022-02-01 | Orionis Biosciences BV | CD8 binding agents |
EP3909978A1 (en) | 2016-02-05 | 2021-11-17 | Orionis Biosciences BV | Clec9a binding agents and use thereof |
US11001631B2 (en) | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
US10988538B2 (en) | 2016-02-05 | 2021-04-27 | Orionis Biosciences BV | Bispecific signaling agents and uses thereof |
US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
EP4059957A1 (en) | 2016-02-05 | 2022-09-21 | Orionis Biosciences BV | Bispecific signaling agents and uses thereof |
JP2019507762A (en) * | 2016-03-07 | 2019-03-22 | ブイアイビー ブイゼットダブリュー | CD20 binding single domain antibody |
CN109069573A (en) * | 2016-03-07 | 2018-12-21 | 弗拉芒区生物技术研究所 | In conjunction with the single domain antibody of CD20 |
EP4276114A3 (en) * | 2016-03-07 | 2024-02-21 | Vib Vzw | Cd20 binding single domain antibodies |
EP4276114A2 (en) | 2016-03-07 | 2023-11-15 | Vib Vzw | Cd20 binding single domain antibodies |
WO2017153402A1 (en) | 2016-03-07 | 2017-09-14 | Vib Vzw | Cd20 binding single domain antibodies |
WO2017153345A1 (en) * | 2016-03-07 | 2017-09-14 | Vib Vzw | Cd20 binding agents and uses thereof |
US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
EP3426278B1 (en) * | 2016-03-07 | 2024-01-03 | Vib Vzw | Cd20 binding single domain antibodies |
CN109069573B (en) * | 2016-03-07 | 2022-04-05 | 弗拉芒区生物技术研究所 | Single domain antibodies that bind CD20 |
US11753463B2 (en) | 2016-05-13 | 2023-09-12 | Orionis Biosciences BV | Therapeutic targeting of non-cellular structures |
WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
WO2017194782A2 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Therapeutic targeting of non-cellular structures |
US11236141B2 (en) | 2016-05-13 | 2022-02-01 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
WO2018077893A1 (en) | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
US11084859B2 (en) | 2016-10-24 | 2021-08-10 | Orionis Biosciences BV | Targeted mutant interferon-gamma and uses thereof |
US11384154B2 (en) | 2017-02-06 | 2022-07-12 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
US10906985B2 (en) | 2017-02-06 | 2021-02-02 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
WO2018144999A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
WO2018141964A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences Nv | Targeted chimeric proteins and uses thereof |
WO2018146074A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
US11246911B2 (en) | 2017-02-07 | 2022-02-15 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
US11566072B2 (en) | 2017-08-09 | 2023-01-31 | Orionis Biosciences, Inc. | CD8 binding agents |
US11498966B2 (en) | 2017-08-09 | 2022-11-15 | Orionis Biosciences Inc. | PD-1 and PD-L1 binding agents |
US11896643B2 (en) | 2018-02-05 | 2024-02-13 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
US11440943B2 (en) | 2019-03-28 | 2022-09-13 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
WO2021009332A1 (en) | 2019-07-18 | 2021-01-21 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
WO2022258662A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
WO2024040249A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
WO2024040247A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US20160159875A1 (en) | 2016-06-09 |
SG11201600165WA (en) | 2016-02-26 |
KR102305608B1 (en) | 2021-09-28 |
JP2016529232A (en) | 2016-09-23 |
AU2014292355A1 (en) | 2016-02-04 |
US9732135B2 (en) | 2017-08-15 |
US20180334489A1 (en) | 2018-11-22 |
US10947288B2 (en) | 2021-03-16 |
US20180334488A1 (en) | 2018-11-22 |
EP3022230A1 (en) | 2016-05-25 |
US20210238247A1 (en) | 2021-08-05 |
IL243459A0 (en) | 2016-03-31 |
IL243459B (en) | 2019-10-31 |
KR20160108292A (en) | 2016-09-19 |
MX2016000721A (en) | 2016-09-07 |
EP3022230B1 (en) | 2019-11-06 |
US20180057555A1 (en) | 2018-03-01 |
CA2918119C (en) | 2022-11-29 |
JP6475712B2 (en) | 2019-02-27 |
SG10202010429YA (en) | 2020-11-27 |
CA2918119A1 (en) | 2015-01-22 |
AU2014292355B2 (en) | 2019-08-01 |
CN105658669A (en) | 2016-06-08 |
US10072059B2 (en) | 2018-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210238247A1 (en) | Targeting of human interferon antagonists | |
Larochette et al. | IL-26, a cytokine with roles in extracellular DNA-induced inflammation and microbial defense | |
Hamilton et al. | Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases | |
Whibley et al. | Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis | |
Campanella et al. | CXCL10 can inhibit endothelial cell proliferation independently of CXCR3 | |
Wolk et al. | Biology of interleukin-22 | |
Hoge et al. | IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling | |
RU2419450C2 (en) | Method of treating and preventing fibrosis by il-21/il-21r antagonists | |
Doodes et al. | IFN-γ regulates the requirement for IL-17 in proteoglycan-induced arthritis | |
US20050214296A1 (en) | Methods of modulating cytokine activity; related reagents | |
Lokau et al. | Biological functions and therapeutic opportunities of soluble cytokine receptors | |
Lalani et al. | Biology of IL-5 in health and disease | |
Chiricozzi et al. | Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential | |
JP2009543579A (en) | WSX-1 / p28 as a target for anti-inflammatory response | |
Ruzek et al. | Dual blockade of interleukin-1β and interleukin-17A reduces murine arthritis pathogenesis but also leads to spontaneous skin infections in nonhuman primates | |
JP2023538919A (en) | CD25-biased anti-IL-2 antibody | |
TAVERNIER | TARGETING OF HUMAN INTERFERON ANTAGONISTS-Patent Information | |
BR112016001122B1 (en) | FUSION PROTEIN COMPRISING AN INTERFERON ANTAGONIST AND A TARGETING FRACTION | |
TAVERNIER et al. | Patent 2918119 Summary | |
Zhou | The function of IL-17F in infection and inflammation | |
CN116783213A (en) | CD25 biased anti-IL-2 antibodies | |
Moncada Vélez et al. | Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome | |
Ono et al. | Accessory Protein-Like Is Essential for |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14734166 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 243459 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2918119 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016526507 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14905348 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/000721 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20167002677 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016001122 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2014292355 Country of ref document: AU Date of ref document: 20140701 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014734166 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112016001122 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160118 |